secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001193125-21-237716
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health names co-CEOs, splits oncology and screening groups; adds Meghan Joyce to board
--------------------------------------------------------------------------------

- Helmy Eltoukhy and AmirAli Talasaz appointed co-CEOs effective Aug 5, 2021; Eltoukhy becomes Chairman.
- Talasaz steps down as COO but remains President; Eltoukhy leads oncology, Talasaz screening division.
- Meghan Joyce, Oscar Health COO/EVP, named independent director; joined audit and compensation committees.
- Joyce received initial stock option and RSU awards each valued at $362,500 under director compensation plan.
- Company plans blood-based screening LDT launch in 2022 and cites recent launches of Reveal, TissueNext, Response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/d212126d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-237716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer